Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPFZ.L Regulatory News (PFZ)

  • There is currently no data for PFZ

Form 38.5(a) - Pfizer Inc

23 Nov 2015 18:11

RNS Number : 6886G
JPMorgan Securities Plc
23 November 2015
 

Ap24

 

FORM 38.5(a)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(a) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITH RECOGNISED INTERMEDIARY STATUS AND DEALING IN A CLIENT-SERVING CAPACITY

 

1. KEY INFORMATION

 

Name of exempt principal trader

J.P. Morgan Securities plc

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common Stock

Date of dealing

20 November 2015

 

2. DEALINGS (Note 2)

 

(a) Purchases and sales

 

Total number of relevant secuities acquired

Highest price paid (EUR)(Note 3)

Lowest price paid (EUR)

(Note 3)

 

Total number of securities disposed

Highest price received (USD) (Note 3)

Lowest price received (EUR)

(Note 3)

563

30.4850

30.4750

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 4)

Number of relevant securities

(Note 5)

Price per unit (EUR)

(Note 3)

Equity Swap

Long

563

30.4751

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 5)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 3)

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 3)

Ap25

 

 

 

3.  OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securities under any option referred to on this form or relating to the voting rights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form is referenced. If none, this should be stated.

 

 

 

 

 

 

Date of disclosure

23 November 2015

Contact name

Tung Le

 

Telephone number

020 7742 7272

Name of offeree/offeror with which connected

Allergan Plc

Nature of connection (Note 6)

Adviser to Allergan Plc

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FERUORWRVKAAUAA
Date   Source Headline
20th May 20143:16 pmRNSForm 8.3 - Pfizer Inc
20th May 20143:13 pmRNSForm 8.3 - [AstraZeneca PLC]
20th May 20143:13 pmRNSForm 8.3 - Pfizer Inc
20th May 20143:10 pmRNSForm 8.3 - Pfizer Inc.
20th May 20142:59 pmRNSForm 8.5 (EPT/RI) Replacement Pfizer Inc
20th May 20142:56 pmRNSForm 8.3 - [PFIZER INC]
20th May 20142:55 pmRNSForm 8.3 - Pfizer Inc
20th May 20142:53 pmBUSForm 8.3 - Pfizer Inc
20th May 20142:30 pmRNSForm 8.3 - Astrazeneca PLC
20th May 20142:30 pmBUSForm 8.3 - Pfizer Inc.
20th May 20142:17 pmBUSForm 8.3 - Pfizer Inc.
20th May 20141:23 pmRNSForm 8.3 - AstraZeneca Plc
20th May 20141:20 pmRNSForm 8.3 - Pfizer Inc
20th May 20141:19 pmRNSForm 8.3 - Pfizer Inc
20th May 20141:16 pmRNSForm 8 (DD) - Pfizer Inc.
20th May 20141:14 pmRNSForm 8.3 - AstraZeneca Plc
20th May 201412:39 pmRNSForm 8.5 (EPT/RI)
20th May 201412:38 pmRNSForm 8.5 (EPT/NON-RI)
20th May 201412:34 pmRNSForm 8.5 (EPT/RI)-Pfizer Inc.
20th May 201412:27 pmRNSForm 8 (DD) - [Pfizer Inc]
20th May 201412:02 pmRNSForm 8.5 (EPT/RI) Pfizer Inc
20th May 201412:02 pmRNSForm 8.5 (EPT/RI) Pfizer Inc
20th May 201412:02 pmRNSForm 8.5 (EPT/RI) - Pfizer Inc
20th May 201411:59 amRNSForm 8.5 (EPT/RI) Pfizer Inc
20th May 201411:55 amRNSForm 8.3 - Pfizer Inc.
20th May 201411:55 amBUSForm 8.3 - Pfizer Inc
20th May 201411:43 amRNSForm 8.5 (EPT/RI)
20th May 201411:40 amRNSForm 8 (DD) - [Pfizer Inc]
20th May 201411:00 amRNSRule 2.10 Announcement
20th May 201410:59 amRNSReplacement: Final Proposal to AstraZeneca
20th May 201410:47 amRNSForm 8.3 - Pfizer Inc
20th May 20149:47 amRNSRule 2.10 Announcement
20th May 20147:00 amRNSPFIZER FINAL PROPOSAL TO ASTRAZENECA
19th May 20144:52 pmRNSForm 8.3 - Pfizer Inc
19th May 20144:32 pmRNSForm 8 (DD) - [Pfizer Inc] - Amendment
19th May 20143:35 pmRNSForm 8 (DD) - Pfizer Inc.
19th May 20143:33 pmRNSForm 8.3 - Pfizer Inc
19th May 20143:28 pmRNSForm 8.3 - Pfizer Inc.
19th May 20143:27 pmRNSForm 8.3 - Pfizer Inc
19th May 20143:26 pmBUSForm 8.3 - Pfizer Inc
19th May 20143:25 pmRNSForm 8.3 - [PFIZER INC]
19th May 20143:23 pmRNSForm 8.3 - Astrazeneca PLC
19th May 20143:23 pmBUSForm 8.3 - Pfizer Inc.
19th May 20143:09 pmRNSForm 8.5 (EPT/RI) Pfizer Inc
19th May 20142:44 pmRNSForm 8.3 - Pfizer Inc
19th May 20142:38 pmRNSForm 8.5 (EPT/NON-RI)AMENDMENT
19th May 20142:31 pmBUSForm 8.3 - Pfizer Inc
19th May 20142:09 pmRNSForm 8.3 - Pfizer Inc
19th May 20141:14 pmBUSForm 8.3 - Pfizer Inc.
19th May 20141:01 pmRNSForm 8.3 - AstraZeneca Plc

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.